Global Burns Pipeline Review, H2 2016: 17 Companies & 29 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Burns - Pipeline Review, H2 2016" report to their offering.

Burns pipeline therapeutics constitutes close to 29 molecules. Out of which approximately 27 molecules are developed by Companies and remaining by the Universities

Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 2, 11, 5 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Burns Overview
  3. Therapeutics Development
  4. Pipeline Products for Burns - Overview
  5. Pipeline Products for Burns - Comparative Analysis
  6. Burns - Therapeutics under Development by Companies
  7. Burns - Therapeutics under Investigation by Universities/Institutes
  8. Burns Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Burns - Products under Development by Companies
  13. Burns - Products under Investigation by Universities/Institutes
  14. Burns - Companies Involved in Therapeutics Development
  • Adocia
  • AlgiPharma AS
  • Amarantus Bioscience Holdings, Inc.
  • American Gene Technologies International Inc.
  • Biogenomics Limited
  • CytoTools AG
  • Destiny Pharma Limited
  • Lakewood-Amedex Inc
  • Madam Therapeutics B.V.
  • MediWound Ltd.
  • Mitochon Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Se-cure Pharmaceuticals Ltd.
  • Sinclair Pharma Plc
  • Stratatech Corporation
  • Tissue Therapies Limited
  • USV Pvt Ltd

For more information about this report visit http://www.researchandmarkets.com/research/pdks69/burns_pipeline

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Dermatological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Dermatological Drugs